These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32469278)

  • 1. Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists.
    Barrios V; Escobar C; Gómez-Doblas JJ; Fernández-Dueñas J; Garrido RR; Rodríguez JP; Sánchez JU; Arellano-Rodrigo E; Donado E;
    J Comp Eff Res; 2020 Jun; 9(9):615-625. PubMed ID: 32469278
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
    Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
    J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
    Choi EK; Lee YS; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D; Oh YS
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33184127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simic D; Skride A; Tang W; Trusz-Gluza M; Vesely J; Vishnepolsky T; Vrabec M
    Open Heart; 2020; 7(1):e001202. PubMed ID: 32257246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation.
    Zhao J; Zhou D; Chen M; Zhuo C; Lin Z; Zheng L; Wang Q
    J Cardiovasc Med (Hagerstown); 2020 Mar; 21(3):200-208. PubMed ID: 31977539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
    Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
    Blin P; Dureau-Pournin C; Cottin Y; Bénichou J; Mismetti P; Abouelfath A; Lassalle R; Droz C; Moore N
    Br J Clin Pharmacol; 2019 Feb; 85(2):432-441. PubMed ID: 30423205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
    Carmo J; Moscoso Costa F; Ferreira J; Mendes M
    Thromb Haemost; 2016 Sep; 116(4):754-63. PubMed ID: 27465747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.